Combined Use of Dexmedetomidine and Hydrocortisone to Prevent New Onset AF After CABG Surgery
Status:
Recruiting
Trial end date:
2023-07-25
Target enrollment:
Participant gender:
Summary
Atrial fibrillation (AF) occurs in 20% to 40% of patients after Coronary artery bypass
grafting (CABG) and is associated with numerous detrimental sequelae. In postoperative
period, the patient may be exposed to several proarrhythmogenic factors as increased
endogenous catecholamines, inflammatory and oxidative mediators secondary to surgical stress
and the systemic response to cardiopulmonary bypass, use of inotropic support. Steroids
suppress the release of the above-mentioned inflammatory mediators. Dexmedetomidine is
sympatholytic, along with anti-inflammatory properties. so combined use of both drugs may
have synergistic effect to prevent post operative AF (POAF)